The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Incyte will pay $750 million to buy Escient Pharmaceuticals and its pipeline of small molecule drugs for inflammatory conditions like chronic urticaria.

    Updated April 23, 2024
  • A photo of CureVac headquarters in Tuebingen, Germany
    Image attribution tooltip
    Courtesy of CureVac AG
    Image attribution tooltip

    CureVac to cut costs in restructuring

    The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will eliminate 150 positions.

  • A person uses laboratory equipment in Endeavor Biosciences' offices.
    Image attribution tooltip
    Permission granted by Endeavor Biosciences
    Image attribution tooltip
    Emerging biotech

    Endeavor pulls in $132M to back cancer, lung disease drugs

    Led by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two prospects that originated in the labs of other drugmakers.

    Updated 21 minutes ago
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis raises forecasts as top drug sales beat Wall Street estimates

    Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

  • Giovanni Caforio, chairman of the board and CEO of Bristol-Myers Squibb Co., testifies before the Senate Finance Committee on "Drug Pricing in America: A Prescription for Change, Part II" February 26,
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Former Bristol Myers CEO tapped as Novartis’ next board chair

    Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Cancer drug startup Lirum Pharmaceuticals set terms for what could be the 11th IPO so far this year. But it would also be one of the smallest, with about $25 million in anticipated proceeds.

    Updated April 19, 2024
  • An image of a neural cell, colored red, is seen on a black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Neurocrine scores surprise win with depression drug

    Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.

  • The front entrance of the Food And Drug Administration headquarters building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA rejects Abeona cell therapy, asks for more manufacturing data

    The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.

    FDA
  • A U.S. flag flying above a building showing a sign with the word Lilly written in red.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly to buy injectable drug plant in manufacturing ramp-up

    The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

  • An illustration of immune system T cells attacking cancer cells.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Bristol Myers taps startup to boost cell therapy production

    A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of CAR-T treatments for cancer.

  • Photo of Takeda Pharmaceutical's global headquarters in Japan.
    Image attribution tooltip
    Courtesy of Takeda Pharmaceuticals
    Image attribution tooltip

    Pharmas form joint venture to jumpstart Japanese drug research

    A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.

  • A scientific illustration of amyloid plaques and neurons, colored in blue and orange.
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Eisai hunts for next Alzheimer’s drug with new research pact

    A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.

  • An Ipsen site in Wrexham, UK.
    Image attribution tooltip
    Courtesy of Ipsen
    Image attribution tooltip

    Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

    The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA. 

  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Alvotech deal could heighten biosimilar pressure on Humira

    The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.

  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche wins FDA OK for Alecensa in early lung cancer

    Alecensa is the first targeted drug available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.

    FDA
  • A person sits in an office chair next to a sign reading Cerevel.
    Image attribution tooltip
    Permission granted by Cerevel Therapeutics
    Image attribution tooltip

    Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

    Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Emerging biotech

    Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

    It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.

  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex begins bid for US approval of non-opioid painkiller

    The biotech has begun a rolling submission of a closely watched drug that’s important to its future, but faces questions of sales potential.

    FDA
  • Anne Wojcicki speaking event
    Image attribution tooltip
    Brad Barket via Getty Images
    Image attribution tooltip

    23andMe CEO plans to take company private

    Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly obesity drug shows benefit in sleep disorder study, pointing to new use

    Positive data for Lilly’s medicine tirzepatide in sleep apnea are the latest signal the benefits of GLP-1 agonists could extend beyond diabetes and weight loss.

  • An illustration of two neurons, colored blue and purple
    Image attribution tooltip
    noparrit via Getty Images
    Image attribution tooltip

    Sage’s cognition drug fails in Parkinson’s study

    Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Stelara biosimilar from Alvotech, Teva approved by FDA

    The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.

  • Damaged hospital Ukraine
    Image attribution tooltip
    Chris McGrath via Getty Images
    Image attribution tooltip

    Ukraine was pharma’s clinical trial ‘darling.’ As war drags on, will the industry return?

    While some new drug studies are getting underway, activity is still far below bustling pre-war levels.

  • A portrait of Uwe Schoenbeck at Canaan Partners.
    Image attribution tooltip
    Permission granted by Canaan
    Image attribution tooltip

    Canaan hires Pfizer executive, reels in $100M for biotech investing

    The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.

  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J sees mixed performance from new multiple myeloma drugs

    Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders."